Using scRNA-seq in two orthotopic glioma models (GL261 and CT-2A) and in a genetically engineered mouse glioma model (EGFRvIII+/TP53-/PTEN-), Kim and colleagues identified CD169+ (SIGLEC1) MDMs, induced by IFN-γ, as a beneficial GAM subset contributing to antitumor immunity (33). Here, SIGLEC1 is linked to glioma.